Baird Downgrades Immutep to Neutral, Lowers Price Target to $1
Benzinga Newsdesk 8 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Baird analyst Joel Beatty downgrades Immutep (NASDAQ:IMMP) from Outperform to Neutral and lowers the price target from $7 to $1.
Baird analyst Joel Beatty downgrades Immutep (NASDAQ:IMMP) from Outperform to Neutral and lowers the price target from $7 to $1.